Ignite Creation Date:
2024-05-06 @ 2:05 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04216121
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2019-12-09
Brief Title:
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
Sponsor:
Universitaire Ziekenhuizen KU Leuven
Organization:
Universitaire Ziekenhuizen KU Leuven
Study Overview
Official Title:
Local AblativeTherapy for Oligoprogressive Non-Small-Cell Lung Cancer Treated With First-line OSImertinib
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LAT-FLOSI
Brief Summary:
To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment the repeated use of LAT to 3 OP lesions and continuation of first-line osimertinib improves the median progression-free survival by more than 3 months ie PFS2-PFS1 3 months
Detailed Description:
The repeated use of LAT to 3 OP lesions with continuation of first-line osimertinib is endorsed by international guidelines NCCN ESMO
In this phase IIb prospective non-randomized observational trial we want to document the benefit of LAT in this patient cohort
In this phase IIb prospective non-randomized observational trial we want to document the benefit of LAT in this patient cohort
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None